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Purpose: To study the clinical, histological, in vivo confocal microscopic, and molecular profile in a family with gelatinous
drop-like corneal dystrophy (GDLD) from north India.
Methods: Two siblings from a consanguineous family presented with clinical features analogous to GDLD. Detailed
clinical evaluations were performed for all the available affected and unaffected members of this family. In vivo confocal
microscopy and histology was done wherever necessary. DNA isolated from peripheral blood samples was subjected to
polymerase chain reaction (PCR) followed by direct sequencing to detect mutations in the tumor-associated calcium signal
transducer 2 (TACSTD2) gene. Protein modeling studies were done to asses the effect of the mutation on the protein
structure.
Results: The diagnosis of GDLD was established in the patient and the affected sibling on slit-lamp examinations, which
revealed mulberry-like opacities in the subepithelium and anterior stroma that were confirmed on histopathology. The
findings  of  the  in  vivo  confocal  microscopy  were  consistent  with  those  reported  in  previous  reports.  Sequencing
TACSTD2 revealed a novel homozygous missense mutation c.356G>A, leading to amino acid substitution C119Y in the
two affected siblings. The mutation was found to be pathogenic on Sorting Intolerant From Tolerant (SIFT) analysis and
was not found in normal controls and unaffected individuals of the family. A synonymous, previously reported, single
nucleotide polymorphism (SNP; rs13267) was also seen in all the individuals of the family. Protein modeling studies
involving wild-type and mutant protein indicated an exposed cysteine residue in the mutant protein.
Conclusions: A novel TACSTD2 C119Y mutation leading to an amino acid substitution was identified in two affected
siblings of a family. Protein modeling studies revealed an exposed cysteine residue, which might cause interchain disulfide
bond formation and protein aggregation leading to disturbed cell junctions of the corneal epithelium.
Gelatinous drop-like corneal dystrophy (GDLD; OMIM
204870), first described by Nakaizumi [1], is a rare type of
primary amyloidosis, with highest prevalence reported from
Japan (1 in 30,000). Clinically, the dystrophy is characterized
by  an  accumulation  of  yellowish-white,  mulberry-like,
gelatinous, amyloid masses in the subepithelial region of the
cornea.  The  accumulation  of  these  masses  causes  loss  of
vision, foreign-body sensation, photophobia, and lacrimation.
GDLD  usually  appears  in  the  first  decade  of  life,  and
neovascularization of the subepithelial and superficial stroma
is seen in the later stages. Patients often require multiple
surgical interventions as the disease is reported to recur within
a few years.
GDLD is an autosomal recessive disorder and is known
to be caused from mutations in the tumor-associated calcium
Correspondence  to:  Dr.  Arundhati  Sharma,  Associate  Professor,
Laboratory  of  Cyto-Molecular  Genetics,  Room  No.  1015,
Department of Anatomy, All India Institute of Medical Sciences,
New  Delhi  110029,  India;  Phone:  91-11-26593489;  FAX:
91-11-26588641;  email:  arundhati_sharma@yahoo.com  or
arundhatisharma1@gmail.com
signal transducer 2 (TACSTD2) gene located on the short arm
of  chromosome  1  [1p32]  [2].  Analysis  of  patients  from
different ethnic backgrounds shows the presence of genetic
heterogeneity [3]. TACSTD2 is 2.07 kb in length and has one
exon  encoding  the  tumor-associated  antigen,  which  is  a
transmembrane glycoprotein of 323 amino acids. This protein
is a monomeric cell surface glycoprotein expressed in the
cornea,  trophoblasts,  and  in  most  carcinomas  [4,5].  Its
function is largely unknown and is speculated to act as a cell–
cell adhesion receptor in cancer cells and as a calcium signal
transducer [5]. It has been speculated that the loss of function
of  the  gene  in  corneal  tissue  results  in  an  increased
permeability of corneal epithelium, resulting in the GDLD
phenotype.  To  date,  24  mutations  (Table  1)  have  been
identified  in  TACSTD2  in  patients  affected  with  GDLD
[5-7]. In the present study we aimed to identify the underlying
mutations  in  TACSTD2  in  the  family  and  for  genotype–
phenotype  correlation.  Protein  homology  modeling  and
molecular dynamics (MD) simulations were performed to
assess the structural implications of the underlying mutation
on the protein conformation.
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729METHODS
Patients and control subjects: The study adhered to the tenets
and declaration of Helsinki, and the protocol was approved by
the Institutional Ethics Committee of the All India Institute of
Medical Sciences (AIIMS). The patients, an 18-year-old male
and his 10-year-old sister, presented at the Cornea Clinic of
Dr. Rajendra Prasad Center for Ophthalmic Sciences, All
India Institute of Medical Sciences (New Delhi, India) with
diminution of vision, photophobia, and lacrimation when he
was 6 years old and his sister was 8 years old.
Detailed  pedigree  information  was  collected.  All  the
available family members—their parents and one unaffected
sibling—were clinically examined (Figure 1). Diagnosis of
GDLD was based on detailed clinical evaluation that included
slit-lamp  examination,  in  vivo  white-light  confocal
microscopy, specular microscopy, pachymetry, orbscan, and
ultrasound for posterior segment evaluation.
A total of 50 healthy volunteers with no ocular or other
disorders matched for age (range between 8-20 years) and sex
(25 males and 25 females) formed the controls. From both the
patients and controls, 5 ml of peripheral venous blood sample
was collected in EDTA after taking informed consent and
explaining the nature and possible consequences of study
participation. These samples were processed immediately for
DNA extraction.
Histopathology: The brother underwent surgical intervention,
and  histopathological  evaluations  were  performed  on  the
corneal tissue sample. It was sectioned and analyzed with light
microscopy after staining with hematoxylin and eosin and
Congo red stains.
In vivo confocal microscopy: In vivo confocal microscopy
was performed using ConfoScan 4.0 (Nidek, Inc., Freemont,
CA) attached to an immersion lens (Achroplan 40X/0.75 W).
The central cornea was examined after instilling a drop of
0.5%  proxy  metacine  hydrochloride  (Paracaine,  Sunways,
Mumbai, India). Gen Teal gel (Novartis India Ltd, Hyderabad,
India) was used as a coupling medium to cover the front
surface  of  the  immersion  lens.  The  images  had  an  axial
resolution of 10 µm.
Mutation  analysis:  Genomic  DNA  was  extracted  from
peripheral blood samples using a DNeasy kit (Qiagen, GmbH,
Hilden, Germany) The DNA was amplified using the primer
pairs  described  previously  (Table  2)  [6].The  cycling
conditions were 15 min denaturation at 95 °C, followed by 35
cycles of 94 °C for 45 s, 58 °C for 30 s, 72 °C for 1 min 30 s,
and a final extension at 72 °C for 5 min. The reaction mixture
of 25 μl was prepared using 200 ng genomic DNA, primers
(0.5  µM  each),  MgCl2  (1.5  mM),  deoxyribonucleotide
triphosphates (dNTPs; 0.2 mM), 1× PCR buffer (containing
10 mM TRIS-HCl, pH 8.3, 50 mM KCl; Roche, Applied
TABLE 1. TACSTD2 MUTATIONS REPORTED IN VARIOUS STUDIES.
Study
number
Mutation Amino acid change Reference
1 c.2T>G Met1Arg [6]
2 c.84insG 28fsThrXGlu93X [7]
3 c.198C>A Cys66X [6]
4 c.250A>T Lys84X [6]
5 c.322T>C Cys108Arg [6]
6 c.341T>G Phe114Cys [7]
7 c.352C>T Gln118X [6]
8 c.352C>G Gln118Glu [6]
9 c.355T>A Cys119Ser [6]
10 c.480delC His160fs174GluX [7]
11 c.493_494insCCACCGCC Gly165AlafsX15 [6]
12 c.509C>A Ser170X [6]
13 c.519dupC Ala174ArgfsX43 [6]
14 c.526_576del51 del.176_192 [7]
15 c.551A>G p Tyr184Cys [6]
16 c.557T>C Leu186Pro [6]
17 c.564delC Lys189SerfsX82 [6]
18 c.581T>A Val194Glu [6]
19 c.619C>T Gln207X22 [6]
20 c. 632delA Gln211ArgfsX60 [6]
21 c.653delA Asp218ValfsX53 [6]
22 c.679G>A Glu227Lys [7]
23 c.772_783delATCTATTACCTGinsT lle258X 772 to 783del [6]
24 c.811delA Lys271SerfsX26 [6]
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730Biosystems,  Foster  City  CA),  and  Taq  polymerase  (1  U;
Roche, Applied Biosystems).
The amplified products of patients and controls were
sequenced bidirectionallly after purification with Qiaquick kit
(Qiagen) with BigDye Terminator Mix version 3.1 (Applied
Biosystems), and were then analyzed on an ABI-3100 Genetic
Analyzer (ABI). Nucleotide sequences for the coding regions
were compared with the nucleotide sequence of the published
TACSTD2 human cDNA (ENST00000371225).
In silico analysis: This was done using the Sorting Intolerant
From  Tolerant  (SIFT)  tool,  which  generates  multiple
alignments of the sequence over different species to look at
the conserved sequences of a gene; it assesses the conserved
amino  acid  positions  and  analyzes  the  effect  of  missense
changes on the conserved structure of proteins over the course
of evolution. The SIFT tool assigns a score to the mutations,
and the score of <0.05 is considered potentially damaging.
Homology modeling of mutant protein: A search through the
Protein Data Bank revealed that the structural template was
available only for the thyroglobulin type 1A (TY) domain of
the TACSTD2 protein. The TY domain of TACSTD2 in the
present case is the domain that harbors the single C119Y
mutation. In an attempt to examine the structural implications
of this mutation, homology modeling and MD simulations
were performed using the template of the TY domain. The
model of the native protein was built involving the stretch
from  89  to  145  amino  acid  residues  by  following  a  fold
prediction protocol with the help of the Phyre server [8]. The
homology model of the native domain was built using the
three-dimensional  X-ray  crystal  structure  of  major
histocompatibilty complex (MHC) class II-associated P41 II
fragment (PDB code: 1ICF) as a template with the protein
modeling module of Discovery Studio 2.0 (Messrs; Accelrys,
San Diego, CA). Mutant (C119Y) was generated by altering
the  corresponding  residue,  and  the  resulting  native  and
mutated structures were minimized separately employing MD
simulation.  The  sequence  analysis  of  the  TY  repeat  of
TACSTD2 (wild type) showed that the protein contains six
conserved cysteine residues, five of which could be modeled
from this structural template.
RESULTS
Clinical findings: Slit-lamp examination of the 18-year-old
patient with GDLD revealed bilateral, advanced, mulberry-
like, elevated, whitish, nodular, vascularized opacities in the
subepithelial  region  (Figure  2A,B).  He  had  previously
Figure 1. Pedigree of the family with gelatinous drop like dystrophy (GDLD). Filled boxes represent individuals affected with GDLD. Open
boxes represent unaffected individuals. Arrowhead indicates the proband. A double line indicates presence of consanguinity in the family.
The numerals shown below the symbols indicate the age of the individuals.
TABLE 2. GDLD PCR PRIMER SEQUENCES.
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731undergone penetrating keratoplasty in the right eye at our
hospital in the year 2000 and a lamellar keratoplasty of the left
eye in 2002. In the year 2008 he presented with recurrence of
dystrophies in both eyes. He again underwent deep anterior
lamellar keratoplasty in the left eye. Slit-lamp examination at
1-year follow-up revealed the best corrected visual acuity for
the left eye as 20/80.
The affected younger sister, who was examined at 10
years of age, had photophobia and lacrimation in both eyes
for the past 2 years. Her BCVA was 20/80 in the right eye and
20/60 in the left eye. Slit-lamp examination revealed band-
shaped  corneal  opacities  in  the  interpalpebral  area  of  the
cornea  of  both  eyes,  with  several  gelatinous  prominences
above the band-shaped opacity in the right eye (Figure 2C).
There was vascular invasion from the inferior limbus into the
clear  cornea  in  the  left  eye  (Figure  2D).  No  surgical
intervention had been advised as the patient was not visually
handicapped and was comfortable with tear substitutes.
Slit-lamp  examinations  established  the  diagnosis  of
GDLD in the two siblings. Clinical evaluation of the parents
and  the  unaffected  sibling  did  not  reveal  any  ocular
abnormalities.
In vivo confocal microscopy: In vivo confocal microscopy of
the affected brother revealed homogenous reflective material
at the basal epithelium with well demarcated cell borders. The
Bowman’s layer was replaced with this reflective material.
Only the superficial epithelium was apparent, while sub-basal
Figure 2. Clinical photomicrographs of the affected individuals of the family. The right eye (A) and left eye (B) show advanced paracentral
mulberry like deposition with nodular opacification and neovascularization in the affected brother. Right eye (C) of the affected sibling shows
typical white sub-epithelial nodules with mulberry pattern in the central cornea and the left eye (D) of the same affected sibling shows band
like opacity in the interpalpebral area with neovascularization.
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732Figure 3. In vivo confocal microscopic
findings of the affected individual. A:
Superficial epithelial cells and B: basal
epithelial cells with a well-demarcated
cell border and the presence of reflective
material  are  seen.  C:  Stroma/
endothelium is not apparent.
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733Figure 4. In vivo confocal microscopic
findings of the affected sibling. Normal
superficial  epithelium  is  shown  (A).
Basal  epithelim  with  circumscribed
hyperreflectivity is seen (B). Anterior
stroma  shows  globular  drop  like
structures (C).
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734nerve plexus, stroma, and endothelium could not be visualized
(Figure 3).
In  vivo  confocal  microscopy  of  the  affected  sister
revealed a normal superficial epithelium with homogenous
reflective  material  at  the  basal  epithelium  with  well
demarcated cell borders. In addition, circumscribed hyper-
reflectivity and many drop-like globular structures were seen
in the left eye, manifesting with a band-like opacity (Figure
4). The Bowman’s membrane was replaced with the reflective
material, the sub-basal nerve plexus was not apparent in either
eye;  however,  the  underlying  stroma,  keratocytes,  and
endothelium were normal.
Histological findings: Histopathology confirmed the presence
of  amyloid  in  the  cornea  on  staining  with  Congo  Red.
Epithelial atrophy was observed. The anterior stroma showed
acellular  eosinophilic  deposits  in  the  subepithelium  and
Figure 5. Histopathological findings. A: Hematoxylin and eosin staining at 20× reveals atrophied overlying epithelium and Bowman’s
membrane. The subepithelium and superficial stroma are seen containing eosinophilic material. B: Amyloid deposition was confirmed in the
anterior and posterior stroma as birefringence was seen on viewing under a polarized filter.
Figure 6. Sequencing results of the tumor associated calcium signal transducer 2 (TACSTD2) gene in the family. Partial nucleotide sequence
of the patient (P) shows the novel mutation c.356G>A (C119Y) in comparison to normal control sequence (C). The reverse complement of
the partial nucleotide sequence of the mother (RM) shows the change in heterozygous state. Arrowheads indicate position of the mutation.
Molecular Vision 2010; 16:729-739 <http://www.molvis.org/molvis/v16/a83> © 2010 Molecular Vision
735superficial stroma along its entire length. All the Congo red-
positive  deposits  of  amyloid  exhibited  apple-green
birefringence under polarized light (Figure 5).
Sorting intolerant from tolerant (SIFT) analysis: In silico
analysis  showed  that  position  119  was  conserved  in  all
orthologues. The SIFT tool analysis revealed a score of <0.05
and  predicted  that  the  replaced  amino  acid  is  potentially
damaging and would not be tolerated (Table 3).
Protein modeling: The secondary structure of the TY domain
comprises an antiparallel β-sheet conformation (B1 and B2)
and a helix (H1) joined by loops (L2 and L3). The disulphide
bridge in the domain Cys119–Cys125 is present between the
β-sheets,  and  Cys127–Cys145  stabilizes  the  loop
conformation at the COOH terminal of the domain (Figure 7).
A comparison of the MD conformers in both mutant C119Y
and wild-type structures revealed a very subtle variation in the
overall  geometry  of  the  protein  with  a  root  mean  square
deviation (rmsd) variation of 0.8 Å in the backbone atoms.
The model quality was also checked by the ProsaII server
[8,9] with a Z score of −2.81, which indicates that the score
lies  within  the  range  of  scores  typically  found  for  native
proteins of similar size. The overall geometry of the protein
TABLE 3. MULTIPLE SEQUENCE ALIGNMENT OF TACSTD2 FROM DIFFERENT SPECIES. THE AMINO ACID CYSTEINE (C) AT POSITION 119 CONSERVED IN ALL THE ORTHOLOGS IS
HIGHLIGHTED IN BOLD/RED.
Homo sapiens DGLYDPDCDP EGRFKARQCN QTSVCWCVNS VGVRRTDKGD LSLRCDELVR
Mus musculus DGLYDPECDD KGRFKARQCN QTSVCWCVNS VGVRRTDKGD QSLRCDEVVR
Macaca mulatta DGLYDPDCDE SGLFKAKQCN GTSTCWCVNT AGVRRTDK-D TEITCSERVR
Bos Taurus DGLYDPECDD KGLFKAKQCN GTSTCWCVNT AGVRRTDK-D SEISCSEPVR
Xenopus laevis DGLYDPECET NGVFKARQCN NTDTCWCVNT AGVRRTDKGD KNWKCPELVR
Gallus gallus DGLYDPECEN NGLFKAKQCN GT-TCWCVNT AGVRRTDKHD TDLKCNQLVR
Danio rerio DGIYDPECQS DGKFKAVQCN NTEVCWCVNS AGVRRSDKKD KNIKC-EPAE
Trichoplax adhaerens GVYIPECNP DGSFAGLQCD STKYCWCVNI FGXXXXXXXX XXXXXXXXXX
Figure 7. Schematic representation of both wild type (A) and mutant (B) tumor associated calcium signal transducer 2 (TACSTD2) protein.
The modeled structure is encircled in black. The abbreviations used are: epidermal growth factor (EFG)-like repeat, a thyroglobulin type 1A
(TY) repeat, a transmembrane domain (TM) and a phosphatidylinositol (PIP2)- binding site, L1, L2, L3 are loops, H1 is helix while B1 and
B2 are anti-parallel b-sheets . The free cysteine residue in the mutant protein is depicted by ~S- and disulphide bridges by dashed lines.
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Mutation  analysis:  Direct  sequencing  revealed  a  novel
mutation in TACSTD2 in GDLD. The homozygous missense
mutation C119Y (GenBank GU138371) was seen in both the
affected individuals. The same change was not seen in the
unaffected  brother  and  50  controls  also  sequenced.  The
change was present in the heterozygous state in the parents.
A  previously  reported  synonymous  single  nucleotide
polymorphism (SNP; rs13267) was found in TACSTD2 in all
the family members (Figure 6).is seen to be conserved even in the presence of the C119Y
mutation (Figure 8).
DISCUSSION
Phenotypic variants are known for GDLD [10-12], and no
clear genotype phenotype correlation has been established
[13-15].  In  vivo  confocal  microscopy  can  provide  useful
insight into the disease and thus serve as an important tool in
characterizing  and  identifying  GDLD.  Only  one  report  is
available describing the in vivo confocal microscopy findings
in GDLD [7]. The findings in our case are consistent with
those mentioned in the earlier study.
To  our  knowledge,  this  is  the  first  report  of  a  novel
mutation in patients with GDLD from north India. The C119Y
mutation  in  TACSTD2  co-segregated  with  the  disease
phenotype in the pedigree, whereas no mutations were found
in  the  controls  analyzed.  The  data  show  that  the  C119Y
mutation  in  TACSTD2  is  responsible  for  GDLD  in  these
patients.
To date, approximately 24 different mutations have been
identified  in  TACSTD2  (Table  1).  Q118X  is  the  most
commonly reported mutation [6]. Previous reports have also
suggested  that  amino  acid  substitution  at  position  119  is
responsible for causation of GDLD [15]. Position 119 was
seen  to  be  conserved  among  the  orthologues  by  in  silico
analysis. This part of the TACSTD2 sequence is considered to
encode a functionally important part of the protein [15]. The
40-kDa  TACSTD2  protein  contains  an  epidermal  growth
factor-like repeat, a thyroglobulin repeat, a transmembrane
domain,  and  a  phosphatidylinositol-binding  site  harboring
phosphorylatable  serine  and  threonine  residues  near  the
COOH  terminus  [2].  The  mutation  detected  in  this  study
affects the TY domain of the protein, resulting in loss of the
cysteine residue at position 119, which is involved in disulfide
bond formation. This TY domain is formed by 76 of the 323
amino acids of TACSTD2; loss of a disulfide bond does not
alter the protein structure, and the overall geometry of the
protein  is  conserved,  even  in  the  presence  of  the  C119Y
mutation. This indicates that the disulphide bridge may not be
essential  for  the  stability  of  the  antiparallel  β-sheet
conformation as these are stabilized by hydrogen bonds [16].
On closer analysis, however, a deviation in the secondary
structure element was observed. The mutation leads to the
shortening of one of the β-sheets (B1) by two residues (from
Cys125 to Ser123; Figure 7). The change in the secondary
structure elements could be attributed to the formation of an
additional hydrogen bond between Tyr104 and Tyr119 in the
mutant C119Y protein. This mutation also leads to an extra
free cysteine residue in the protein. The free cysteine residue
(Cys125)  in  the  mutant  protein  is  exposed  to  the  protein
surface (Figure 8). The positioning of this free amino acid
residue indicates that it could be involved in the formation of
disulfide bridges with other similar mutated molecules having
a  free  cysteine  residue.  Therefore,  we  postulate  that  the
formation of molecular dimers as a result of the intermolecule
disulphide bridge from this mutation is probably responsible
for protein aggregation.
The TY domain contains the thyroglobulin type-1 repeat
signature [17] with six conserved cysteines and is thought to
be involved in the control of proteolytic degradation. Studies
using  transfection  assays  have  shown  normal  TACSTD2
protein to accumulate at cell to cell contact borders [18]. It has
Figure 8. Comparison of the wild-type (A) shown in blue and mutant conformers (B) shown in green obtained after Molecular Dynamics
(MD) simulations. Difference in distances of wild type (4.9Ǻ) and mutant (2.5 Ǻ) are indicated. The change in secondary structure element
is due to formation of hydrogen bond interactions shown by dashed lines.
Molecular Vision 2010; 16:729-739 <http://www.molvis.org/molvis/v16/a83> © 2010 Molecular Vision
737also been shown that truncated proteins do not accumulate at
the cell membrane [2] and thus cause disturbances in the cell
to cell and cell to substrate adhesion function, which is evident
by abnormal gaps between surface epithelial cells, disordered
desmosomes, and abnormal basal epithelium [19]. Our protein
modeling  studies  also  show  an  excess  of  free  cysteine
involved in disulphide bond formation with similar mutated
proteins and forming aggregates. We hypothesize that these
aggregates of abnormal proteins accumulate in the cytoplasm
and are unable to reach the cell membrane, thus altering the
cell to cell adhesion function of the corneal epithelium. It has
also been demonstrated that mutated TACSTD2 is associated
with increased cell permeability compared to controls; this
disturbs  the  cell  to  cell  adhesion  and  contributes  to
pathogenesis  of  amyloid  deposition  [19].  Lactoferrin,  a
protein of the lacrimal glands, has been identified in GDLD
amyloid deposits [20] and is thought to originate from the tear
film and penetrate the disturbed cell junctions [19] in the
basement membrane and subepithelial area. These findings,
along  with  the  functional  analysis  of  TACSTD2,  may  be
critical in elucidating the pathogenesis of GDLD.
In conclusion, we report for the first time the clinical, in
vivo microscopic, histologic, genetic, and protein modeling
findings of a family with GDLD. A novel TACSTD2 C119Y
mutation was identified in two affected siblings of a family in
whom in vivo confocal microscopy and histopathology results
were  consistent  with  clinical  findings.  In  addition,
characterization of the mutation using homology modeling
suggested that the exposed cysteine in the mutant protein may
cause interchain disulfide bond formation, leading to protein
aggregates which are unable to reach to the cell boundaries
and accumulate at the cell to cell adhesion borders, thereby
disturbing the cell to cell junctions. This disturbance may lead
to increased permeability of the corneal epithelial cells.
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